Arai T, Yasuda Y, Ito Y, Hayakawa K, Takaya T, Toshima S, Shibuya C, Nawada M, Shibayama M, Yoshimi N, Ito H, Fujiwara H
Dept. of Internal Medicine, Gihoku General Hospital, Gifu, Japan.
Gan To Kagaku Ryoho. 1996 Jun;23(7):881-5.
We studied the correlation between cisplatin and etoposide chemotherapy and GST-pi staining in patients with untreated primary non-small cell lung cancer.
Of patients diagnosed as having primary lung cancer, 27 patients (26 men, 1 woman; median age 74.9 years) with stage III b or over were studied. Histological types included squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. A course of treatment consisted of cisplatin 100 mg/m2/day x one day and etoposide 100 mg/m2/day x 3 days during 28 days. After 2 courses of treatment, the therapeutic effects were judged and examined in relation to immunostaining levels obtained with anti-GST-pi antibody.
Of patients with PR (14), 11 showed GST-pi (-) staining.
There is a correlation between GST-pi staining and the effects of cisplatin and etoposide chemotherapy.
我们研究了未经治疗的原发性非小细胞肺癌患者顺铂和依托泊苷化疗与谷胱甘肽S转移酶π(GST-π)染色之间的相关性。
对诊断为原发性肺癌的患者进行研究,其中27例(26例男性,1例女性;中位年龄74.9岁)为Ⅲb期及以上患者。组织学类型包括鳞状细胞癌、腺癌和大细胞癌。一个疗程包括在28天内给予顺铂100mg/m²/天×1天和依托泊苷100mg/m²/天×3天。2个疗程治疗后,根据抗GST-π抗体获得的免疫染色水平判断并检查治疗效果。
在部分缓解(PR)的患者(14例)中,11例显示GST-π(-)染色。
GST-π染色与顺铂和依托泊苷化疗的效果之间存在相关性。